NASD · Healthcare · Biotechnology · USA
Madrigal Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Madrigal Pharmaceuticals is a biopharmaceutical company that develops treatments for metabolic dysfunction-associated steatohepatitis, a serious liver disease. Its approved medication, Rezdiffra, is an oral thyroid hormone receptor beta agonist available in the United States and Germany. The company also has a pipeline of additional candidates targeting MASH, including a GLP-1 receptor agonist, a DGAT2 inhibitor, and gene-silencing programs.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Madrigal Pharmaceuticals Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.
17 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on MDGL yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-30 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.